Vol 4, No 2 (2019)
Original article
Published online: 2019-02-16
Losartan effects on liver cytochromes CYP3A, CYP2C and CYP2E1 functioning at metabolic syndrome in young and adult rats
Med Res J 2019;4(2):72-79.
Abstract
CYP450-dependent interactions and toxicological consequences of hypoglycemic and antihypertensive
drugs used in treatment of children with metabolic syndrome (MS) remained unclear. Our aim was to carry
out a complex estimation of metabolic syndrome and losartan mediated changes in CYP3A, CYP2C, CYP2E1
mRNA expression, corresponding marker enzymes activities, liver antioxidant system and lipid peroxidation
parameters of adult and pubertal rats. Wistar albino male rats of two age categories (young animals of 21
days age (50–70 g) and adults (160–180 g) were divided into 6 groups (6 animals in each): 1 – Control 1
(intact young rats); 2 – Control 2 (intact adult rats); 3 –young rats with MS; 4 – adult rats with MS; 5 – young
rats with MS+losartan; 6 – adult rats with MS+ losartan. The metabolic syndrome model was induced
by full replacement of drinking water with 20% fructose solution (200 g/l). After 60 days of MS modeling,
investigation of rat liver CYP3A, CYP2C, CYP2E1 mRNA expression, their marker enzymes activities, lipid
peroxidation parameters were carried out. Losartan administration caused increase of CYP3A, CYP2C
and CYP2E1 mRNA expression rates in both age groups. Marker enzymes, glutathione transferase and
reductase rates were normalized only in adult rats. In group of pubertal animals losartan administration led
to CYP3A and CYP2C marker enzymes activities normalization. Liver reduced glutathione contents remained
decreased in both age groups. Thus, losartan demonstrates some age-dependent effectiveness towards
normalization of CYP450 isoforms expression rates, p-nitrophenol hydroxylase, erythromycin-N-demethylase
and diclofenac hydroxylase activities, but not glutathione system and lipid peroxidation rates.
Keywords: metabolic syndromelosartanCYP450pubertalrats
References
- Chu PY, Campbell MJ, Miller SG, et al. Anti-hypertensive drugs in children and adolescents. World J Cardiol. 2014; 6(5): 234–244.
- Hirsch A, Hahn D, Kempná P, et al. Metformin inhibits human androgen production by regulating steroidogenic enzymes HSD3B2 and CYP17A1 and complex I activity of the respiratory chain. Endocrinology. 2012; 153(9): 4354–4366.
- Attia GR, Rainey WE, Carr BR. Metformin directly inhibits androgen production in human thecal cells. Fertil Steril. 2001; 76(3): 517–524.
- Bondarenko LB, Shayakhmetova GM, Voronina AK, et al. Age-dependent features of CYP3A, CYP2C, and CYP2E1 functioning at metabolic syndrome. J Basic Clin Physiol Pharmacol. 2016; 27(6): 603–610.
- Iwamura A, Fukami T, Hosomi H, et al. CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay. Drug Metab Dispos. 2011; 39(5): 838–846.
- Choi DH, Li C, Choi JS. Effects of myricetin, an antioxidant, on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats: possible role of cytochrome P450 3A4, cytochrome P450 2C9 and P-glycoprotein inhibition by myricetin. J Pharm Pharmacol. 2010; 62(7): 908–914.
- Abdulla MH, Sattar MA, Abdullah NA, et al. The contribution of α1B-adrenoceptor subtype in the renal vasculature of fructose-fed Sprague-Dawley rats. Eur J Nutr. 2011; 50(4): 251–260.
- Kamath SA, Kummerow FA, Narayan K. A simple procedure for the isolation of rat liver microsomes. FEBS Letters. 2001; 17(1): 90–92.
- Jäger W, Correia MA, Bornheim LM, et al. Ethynylestradiol-mediated induction of hepatic CYP3A9 in female rats: implication for cyclosporine metabolism. Drug Metab Dispos. 1999; 27(12): 1505–1511.
- Imaoka S, Hashizume T, Funae Y. Localization of rat cytochrome P450 in various tissues and comparison of arachidonic acid metabolism by rat P450 with that by human P450 orthologs. Drug Metab Pharmacokinet. 2005; 20(6): 478–484.
- Koop D. Inhibition of ethanol-inducible cytochrome P 450IIE1 by 3-amino-1,2,4-triazole. Chemical Research in Toxicology. 1990; 3(4): 377–383.
- Wang RW, Newton DJ, Scheri TD, et al. Human cytochrome P450 3A4-catalyzed testosterone 6 beta-hydroxylation and erythromycin N-demethylation. Competition during catalysis. Drug Metab Dispos. 1997; 25(4): 502–507.
- Nekrasova LV, Russkih YaV, Novikov AV, et al. Application of the method (HPLC-tandem high resolution MS) for the drug compounds determination in natural water. Scientific instrumentation [Nauchnoye priborostroenie. 2010; 20(4): 59–66.
- Habig WH, Pabst M, akoby WB. Glutathione-S-Transferases. J. Biol. Chem. 1974; 249(22): 7130–7139.
- Mannervik B, Jemth P. The Glutathione Pathway. Measurement of Glutathione Transferases. Costa LG, Hodgson E, Lawrence DA, Ozolins TR, Reed DJ, Greenlee WF, editors. Current Protocols in Toxicology. N. In: Costa LG, Hodgson E, Lawrence DA, Ozolins TR, Reed DJ, Greenlee WF. ed. Current Protocols in Toxicology. John Wiley & Sons Inc, New York 2005: 2758.
- Sedlak J, Lindsay RH. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Anal Biochem. 1968; 25(1): 192–205.
- Lankford SM, Bai SA, Goldstein JA. Cloning of canine cytochrome P450 2E1 cDNA: identification and characterization of two variant alleles. Drug Metab Dispos. 2000; 28(8): 981–986.
- Stalnaya ID, Gharishvili TG. Method for malone dialdehyde determination with thiobarbituric acid. In: Orechovich VN. ed. Modern Methods in Biology. 66–68, Moscow 1997: 66–68.
- Lucas D, Farez C, Bardou LG, et al. Cytochrome P450 2E1 activity in diabetic and obese patients as assessed by chlorzoxazone hydroxylation. Fundam Clin Pharmacol. 1998; 12(5): 553–558.
- Dey A, Cederbaum AI. Induction of cytochrome P450 2E1 [corrected] promotes liver injury in ob/ob mice. Hepatology. 2007; 45(6): 1355–1365.
- Brill MJE, Diepstraten J, van Rongen A, et al. Impact of obesity on drug metabolism and elimination in adults and children. Clin Pharmacokinet. 2012; 51(5): 277–304.
- Oh SJ, Choi JM, Yun KUk, et al. Hepatic expression of cytochrome P450 in type 2 diabetic Goto-Kakizaki rats. Chem Biol Interact. 2012; 195(3): 173–179.
- Crespo MJ, Altieri PI, Escobales N. Increased vascular angiotensin II binding capacity and ET-1 release in young cardiomyopathic hamsters. Vascul Pharmacol. 2006; 44(4): 247–252.
- Wu JN, Edwards D, Berecek KH. Changes in renal angiotensin II receptors in spontaneously hypertensive rats by early treatment with the angiotensin-converting enzyme inhibitor captopril. Hypertension. 1994; 23(6 Pt 2): 819–822.
- Tsutsumi K, Strömberg C, Viswanathan M, et al. Angiotensin-II receptor subtypes in fetal tissue of the rat: autoradiography, guanine nucleotide sensitivity, and association with phosphoinositide hydrolysis. Endocrinology. 1991; 129(2): 1075–1082.
- Stearns RA, Chakravarty PK, Chen R, et al. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. Drug Metab Dispos. 1995; 23(2): 207–215.
- Shou M, Dai R, Cui D, et al. A kinetic model for the metabolic interaction of two substrates at the active site of cytochrome P450 3A4. J Biol Chem. 2001; 276(3): 2256–2262.
- Bae Jw, Choi Ci, Kim Mj, et al. Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics. Acta Pharmacol Sin. 2011; 32(10): 1303–1308.
- Aguiar M, Masse R, Gibbs BF. Regulation of cytochrome P450 by posttranslational modification. Drug Metab Rev. 2005; 37(2): 379–404.
- Jo Corbin C, Mapes SM, Lee YM, et al. Structural and functional differences among purified recombinant mammalian aromatases: glycosylation, N-terminal sequence and kinetic analysis of human, bovine and the porcine placental and gonadal isozymes. Mol Cell Endocrinol. 2003; 206(1-2): 147–157.
- Yang SH, Choi JS, Choi DH. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors. Pharmacology. 2011; 88(1-2): 1–9.
- Yasar U, Sain-Guven G, Yardimci Y, et al. Effect of atorvastatin on CYP2C9 metabolic activity as measured by the formation rate of losartan metabolite in hypercholesterolaemic patients. Basic Clin Pharmacol Toxicol. 2011; 109(2): 73–77.
- Taavitsainen P, Kiukaanniemi K, Pelkonen O. In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists. Eur J Clin Pharmacol. 2000; 56(2): 135–140.
- Villeneuve JP, Pichette V. Cytochrome P450 and liver diseases. Curr Drug Metab. 2004; 5(3): 273–282.
- Murad HA, Gazzaz ZJ, Ali SS, et al. Candesartan, rather than losartan, improves motor dysfunction in thioacetamide-induced chronic liver failure in rats. Braz J Med Biol Res. 2017; 50(11): e6665.
- Ateyya H, Nader MA, El-Sherbeeny NA. Beneficial effects of rosiglitazone and losartan combination in diabetic rats. Can J Physiol Pharmacol. 2018; 96(3): 215–220.
- Czechowska G, Celinski K, Korolczuk A, et al. The effect of the angiotensin II receptor, type 1 receptor antagonists, losartan and telmisartan, on thioacetamide-induced liver fibrosis in rats. J Physiol Pharmacol. 2016; 67(4): 575–586.
- Roytberh HE. Metabolic syndrome. Scientific Digest. Science. MED-press-inform 2007: 224.
- Lin CH, Yang H, Xue QL, et al. Losartan improves measures of activity, inflammation, and oxidative stress in older mice. Exp Gerontol. 2014; 58: 174–178.